On 7/24/24, Sage Therapeutics Inc (NASDAQ: SAGE) stock suffered a major decline of -20.6%, closing at $10.38. Moreover, exceptionally high trading volume at 208% of normal accompanied the decline. Relative to the market the stock has been extremely weak over the last nine months and has declined -14.6% during the last week.
Current PriceTarget Research Rating
SAGE is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Sage Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Sage Therapeutics has a poor Appreciation Score of 29 and a poor Power Rating of 18, and the Lowest Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment